At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 74 enrolled
Drug / intervention
Fostamatinib Disodium +1 moredrug
Likely dose
Fostamatinib Disodium 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
In Brief
A Phase 3 clinical trial evaluating Fostamatinib Disodium and Placebo for Immune Thrombocytopenic Purpura. Completed, enrolled 74 participants across 35 sites in 9 countries.
Detailed Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Thrombocytopenic Purpura
CountriesAustria, Bulgaria, Czechia, Germany, Norway, Poland, Romania, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartJan 2015
Primary CompletionAug 2016
TodayJul 2026
First PostedMar 3, 2014
Enrollment StartJan 1, 2015
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 12.3 years ago
Interventions
Fostamatinib Disodiumdrug
Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
Placebodrug
Placebo tablet PO bid (morning and evening)